Skip to content

Gut Microbiota and Metabolites in New-onset Atrial Fibrillation after Off-pump Coronary Artery Bypass Grafting and Their Changes

Gut Microbiota and Metabolites in New-onset Atrial Fibrillation after Off-pump Coronary Artery Bypass Grafting and Their Changes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074550
Enrollment
Unknown
Registered
2023-08-09
Start date
2023-08-09
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

POAF:Observational study,inapplicable
non-POAF:Observational study,inapplicable

Sponsors

General Hospital of Northern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) 35-80 years old, regardless of gender; 2) Sinus rhythm before operation, no history of atrial fibrillation and atrial arrhythmia; 3) Selective off-pump coronary artery bypass grafting (bypass grafts were internal mammary artery and/or great saphenous vein); 4)EF>40%; 5) Good compliance, able to cooperate with the completion of follow-up.

Exclusion criteria

Exclusion criteria: 1)Those who do not meet the selection criteria; 2)Emergency or second cardiac surgery; 3)History of arrhythmia, congenital heart disease, valvular heart disease, tumor disease, hyperthyroidism or hypothyroidism recorded by medical documents; 4)Use of antibiotics within two weeks; use of probiotics or yogurt within one week; chronic or acute gastrointestinal disease within one month; 5)Those who need to take class I and class III antiarrhythmic drugs; 6)History of atrial fibrillation ablation and pacemaker implantation; 7)Severe liver and kidney dysfunction (test results exceed 3 times the upper limit of normal value), severe lung disease, coagulation dysfunction; 8)Patients with other diseases requiring radiotherapy, chemotherapy and long-term hormone therapy; 9) Those who have participated in other clinical trials or refused to participate in this trial;

Design outcomes

Primary

MeasureTime frame
preoperative Gut Microbiota ;preoperative plasma metabolites ;postoperative plasma metabolites ;

Countries

China

Contacts

Public ContactWang Huishan

General Hospital of Northern Theater Command

huishanw@126.com+86 177 9099 8997

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026